Market Overview - US stock futures remained steady ahead of delayed data releases that are expected to provide insights into the economy, but are unlikely to alter expectations for interest rate cuts [1] - The S&P 500, Nasdaq 100, and Dow Jones Industrial Average futures showed little movement, following three consecutive gains for US stocks at the start of the week [2] - The S&P 500 is approximately 0.3% away from its all-time high, indicating strong market performance despite previous shifts away from AI and tech stocks [3] Economic Data - Recent data, including a surprising drop in inflation and a lukewarm labor market report, have maintained expectations for interest rate cuts in 2026 [4] - Upcoming data releases include the third quarter GDP and December consumer confidence, which are critical for assessing the health of the US economy [4][5] Company News - Novo Nordisk received FDA approval for its weight-loss pill, Wegovy, which is expected to enhance its market position against US competitor Eli Lilly [5][6] - The approval is significant for Novo Nordisk as it aims to recover from a challenging year marked by declining shares and profit warnings due to increased competition [6]